HOMOCYSTEINE AS RISK FACTOR FOR CARDIOVASCULAR DISEASE IN RENAL TRANSPLANTATION

同型半胱氨酸是肾移植中心血管疾病的危险因素

• 批准号: 6264841
• 负责人: DONALD B HUNNINGHAKE
• 金额: $ 4.48万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264841
• 关键词: cardiovascular disorder; clinical research; clinical trial phase I; disease /disorder proneness /risk; homocysteine; homocystinuria; human subject; human therapy evaluation; kidney transplantation; medical complication; vitamin therapy

This study is determining the frequency and severity of hyperhomocysteinemia in the kidney transplant population. The diagnostic sensitivities of fasting homocysteine and post-methionine homocysteine will be determined. This study will also attempt to define effective vitamin therapies for hyperhomocysteinemia in this population and therby reduce cardiovascular risk. Patients will be assigned to one of six treatment groups based on fasting and post-methionine homocysteine levels. The response to therapy will be assessed at 6 weeks, 12 weeks, and one year. Vitamin therapy will be adjusted in an effort to normalize homocysteine levels.

本研究旨在确定肾移植人群中高同型半胱氨酸血症的频率和严重程度。 将确定空腹同型半胱氨酸和蛋氨酸后同型半胱氨酸的诊断灵敏度。 本研究还将试图确定有效的维生素治疗高同型半胱氨酸血症在这一人群中，从而降低心血管疾病的风险。 根据空腹和蛋氨酸后同型半胱氨酸水平，将患者分配至6个治疗组之一。 将在6周、12周和1年时评估对治疗的反应。维生素治疗将进行调整，努力使同型半胱氨酸水平正常化。